← boardnext 2027-05
VYGR
Voyager Therapeuticsdistress 4/10 · elevated risk$3.04-2%today-43% from 52w high
Lead: Alzheimer's disease · est. market ~$8B (approx, global)
Revenue
pre-revenue
Liquidity
$172M
Runway
1.3 yrs
Shares 1y
+9%
Price & events
-25.9% over 6M
CatalystRating changeDilutionFinancingdashed = today
-1.9%
1D
+0.0%
1W
-17.8%
1M
-24.8%
3M
-24.0%
6M
-7.3%
1Y
-65.7%
2Y
-2.6%
5Y
-58.1%
All
Overview
- Market Cap
- $183.68M
- Volume
- 40.08K
- 52 Week Range
- $2.96 – $5.33
- Total Shares
- 60.42M
- Float Shares
- 44.22M
- Short %
- 6.95%
- % Held by Insiders
- 15.14%
- % Held by Institutions
- 56.44%
- RVOL
- 0.06x
- Beta
- 1.27
Pipeline stages · 1 programs
VY7523
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 1 trials · 1 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2027-05 Estimated 50% readout ~2027-06-15 | Phase 1/2 | VY7523 | Alzheimer's Disease (AD) | — | active not recruiting |
Catalyst news & presentations · 6
- 2026Guided 40%regulatory submissionFiled (NDA/BLA)VY1706 · IND filing expected for VY1706 in 2026.SEC 8-K
- H2 2026Guided 55%readoutVY7523 · Data in Alzheimer's disease patientsSEC 8-K
- second half of 2026Guided 55%trial initiationsecondaryVY1706 · Initiate multi-site, open-label, dose-escalation trial dosing in early AD patients.SEC 8-K
- 2026-08-05Estimated 45%earningsEarningsEarnings releaseyahoo
- 2026-06-01fda agreementVY1706 · FDA cleared Investigational New Drug application for VY1706.SEC 8-K
- 2025regulatory submissionFiled (NDA/BLA)Friedreich's ataxia gene therapy (Neurocrine) · IND filing expected for Friedreich's ataxia gene therapy program.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $15 (+390% upside) · 9 analysts
- 2026-03-17HC Wainwright & Co.Buy
- 2025-11-12HC Wainwright & Co.Buy
- 2025-09-15HC Wainwright & Co.Buy
- 2025-08-07WedbushOutperform
- 2025-04-08HC Wainwright & Co.Buy
- 2025-03-13HC Wainwright & Co.Buy
Competitors — Alzheimer's disease
- BMYBRISTOL MYERS SQUIBB CO$124.5B · D0
- AXSMAxsome Therapeutics, Inc.$12.3B · D0
- ACADACADIA PHARMACEUTICALS INC$4.2B · D0
- DNLIDenali Therapeutics Inc.$3.6B · D2
- NAMSNewAmsterdam Pharma Co N.V.$3.6B · D0
- MPLTMapLight Therapeutics, Inc.$1.5B · D2
- NMRANeumora Therapeutics, Inc.$281M · D5
- PMNProMIS Neurosciences Inc.$125M · D5
- ANVSAnnovis Bio, Inc.$59M · D8
- INMBInmune Bio, Inc.$47M · D5
Recent news
- 2026-07-20H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data - Investing.com Nigeria
- 2026-07-20H.C. Wainwright reiterates Voyager Therapeutics stock rating on tau therapy data - Investing.com
- 2026-07-15Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - Sahm
- 2026-07-14Voyager Therapeutics Drops To US$3.24, Yet Insiders May Have Sold Too Early - simplywall.st
- 2026-07-13Voyager Therapeutics advances tau-silencing gene therapy program - TipRanks
- 2026-07-13Voyager presents six-month data for Alzheimer’s gene therapy - Investing.com UK
- 2026-07-13Voyager Therapeutics Presents Positive GLP Toxicology Data for VY1706 Tau Silencing Gene Therapy in Alzheimer’s Disease, Plans Clinical Trial in 2026 – Minichart - Minichart
- 2026-07-13Voyager Therapeutics (VYGR) Reports Promising VY1706 Data for Al - GuruFocus
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.